{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:50:38Z","timestamp":1777564238376,"version":"3.51.4"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Cefuroxime is frequently used as preoperative antibiotic prophylaxis and may be used for the treatment of septic arthritis. A prerequisite for successful treatment of septic arthritis is the ability of an antibiotic agent to penetrate into the target site. Therefore, the concentration of cefuroxime in synovial fluid was evaluated. Ten patients who underwent elective knee arthroscopy were included in this study. Patients were treated with a single dose of 1,500 mg cefuroxime intravenously, and subsequently, the concentrations in plasma, the interstitial fluid of muscle tissue, and synovial fluid were measured by using microdialysis. Pharmacokinetic\/pharmacodynamic calculations to predict bacterial killing were performed using the epidemiologically defined MIC\n            <jats:sub>90<\/jats:sub>\n            for clinical isolates and CLSI breakpoints. Cefuroxime penetrated excellently into muscle tissue (ratio of the area under the concentration-time curve [AUC] for muscle tissue\/AUC for free plasma, 1.79) and synovial fluid (ratio of the AUC for synovial fluid\/AUC for free plasma, 1.94). The cefuroxime concentration was greater than the MIC\n            <jats:sub>90<\/jats:sub>\n            for\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">S. epidermidis<\/jats:named-content>\n            strains (\u22642 mg\/liter) over the complete dosing interval (the percentage of the dosing interval during which the free cefuroxime concentration exceeded the MIC for the pathogen [\n            <jats:italic>fT<\/jats:italic>\n            <jats:sub>MIC<\/jats:sub>\n            ]). CLSI defines staphylococci with MICs of \u22648 mg\/liter to be susceptible to cefuroxime. For staphylococci with MICs of \u22648 mg\/liter, the\n            <jats:italic>fT<\/jats:italic>\n            <jats:sub>MIC<\/jats:sub>\n            in plasma was 52.5%, while the\n            <jats:italic>fT<\/jats:italic>\n            <jats:sub>MIC<\/jats:sub>\n            in muscle tissue and synovial fluid was 93.6% and 96.3%, respectively. Cefuroxime may be used to treat septic arthritis caused by susceptible bacterial strains (MIC \u2264 8 mg\/liter). The activity of cefuroxime in septic arthritis might be underestimated when relying exclusively on plasma concentrations.\n          <\/jats:p>","DOI":"10.1128\/aac.00992-17","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:40:19Z","timestamp":1502152819000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics of Cefuroxime in Synovial Fluid"],"prefix":"10.1128","volume":"61","author":[{"given":"R.","family":"Schwameis","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Syr\u00e9","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Marhofer","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, Intensive Care Medicine, and Pain Therapy, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Appelt","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Burau","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sarahrudi","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kloft","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universit\u00e4t Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00144-09"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0463-7"},{"key":"e_1_3_2_4_2","volume-title":"Guidance for industry","author":"FDA","year":"1998","unstructured":"FDA. 1998. Guidance for industry. Developing antimicrobial drugs\u2014general considerations for clinical trials. FDA, Rockville, MD. wwwfdagov\/cder\/guidance\/2580dftpdf."},{"key":"e_1_3_2_5_2","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2016","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/07\/WC500210982.pdf."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27425"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152769"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077131"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-011-1554-y"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel163a"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61595-6"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.9.5.741"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg429"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01348-13"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2703"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.03.019"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3548-3553.2003"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-014-2657-7"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(00)00106-X"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7337.588"},{"key":"e_1_3_2_22_2","volume-title":"Guideline on bioanalytical method validation","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2011","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. 2011. Guideline on bioanalytical method validation. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.suppl_A.97"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.8.1210"},{"key":"e_1_3_2_26_2","volume-title":"CLSI document M100-S20","author":"CLSI","year":"2010","unstructured":"CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. CLSI, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00992-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00992-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:46:30Z","timestamp":1645476390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00992-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1128\/AAC.00992-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00992-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2017-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00992-17"}}